An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high- level resistance to 3'-azido-3'-deoxythymidine

Journal of Virology

Volumn 70, Issue 11, 1996, Pages 8010-8018

  Hooker, David J ^a   Tachedjian, Gilda ^a   Solomon, Ajantha E ^a   Gurusinghe, Asitha D ^a   Land, Sally ^b   Birch, Chris ^a,b   Anderson, Jenny L ^a   Roy, Birgit M ^c   Arnold, Edward ^c   Deacon, Nicholas J ^a  

^a MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^b Fairfield Hospital Prairiewood   (Australia)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE; RNA DIRECTED DNA POLYMERASE; TRYPTOPHAN; TYROSINE; VIRUS ENZYME; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL;

EID: 10244227943     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.11.8010-8018.1996     Document Type: Article

References (60)

1. Bachmann, B., W. Luke, and G. Hunsmann. 1990. Improvement of PCR amplified DNA sequencing with the aid of detergents. Nucleic Acids Res. 18:1309.
2. Boucher, C. A. B., E. O'Sullivan, J. W. Mulder, C. Ramautarsing, P. Kellam, G. Darby, J. M. A. Lange, J. Goudsmit, and B. A. Larder. 1992. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J. Infect. Dis. 165:105-110.
3. Boyer, P. L., C. Tantillo, A. Jacobo-Molina, R. G. Nanni, J. Ding, E. Arnold, and S. H. Hughes. 1994. Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. Proc. Natl. Acad. Sci. USA 91:4882-4886.
4. Browne, M. J., K. H. Mayer, S. B. Chafee, M. N. Dudley, M. R. Posner, S. M. Steinberg, K. K. Graham, S. M. Geletko, S. H. Zinner, S. L. Denman, L. M. Dunkle, S. Kaul, C. McLaren, G. Skowron, N. M. Kouttab, T. A. Kennedy, A. B. Weitberg, and G. A. Curt. 1993. 2′ .3′-didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J. Infect. Dis. 167:21-29.
5. Eron, J. J., Y.-K. Chow, A. M. Caliendo, J. Videler, K. M. Devore, T. P. Cooley, H. A. Liebman, J. C. Kaplan, M. S. Hirsch, and R. T. D'Aquila. 1993. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimicrob. Agents Chemother. 37:1480-1487.
6. Fischl, M. A., D. D. Richman, D. M. Causey, M. H. Grieco, Y. Bryson, D. Mildvan, O. L. Laskin, J. E. Groopman, P. A. Volderding, R. T. Schooley, G. G. Jackson, D. T. Durack, J. C. Andrews, S. Nusinoff-Lehrman, D. W. Barry, and the AZT Collaborative Working Group. 1989. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. JAMA 262:2405-2410.
7. Fitzgibbon, J. E., A. E. Farnham, S. J. Sperber, H. Kim, and D. T. Dubin. 1993. Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs. J. Virol. 67:7271-7275.
8. Fitzgibbon, J. E., R. M. Howell, C. A. Haberzettl, S. J. Sperber, D. J. Gocke, and D. T. Dubin. 1992. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob. Agents Chemother. 36:153-157.
9. Furman, P. A., J. A. Fyfe, M. H. St. Clair, K. Weinhold, J. L. Rideout, G. A. Freeman, S. N. Lehrman, D. P. Bolognesi, S. Broder, H. Mitsuya, and D. W. Barry. 1986. Mode of inhibition of the human T-cell lymphotropic virus III by 3′-azido-3′-deoxythymidine. Proc. Natl. Acad. Sci. USA 83:8333-8337.
10. Gao, Q., Z. Gu, M. A. Parniak, X. Li, and M. A. Wainberg. 1992. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine. J. Virol. 66:12-19.
11. Gray, F, L. Belec, C. Keohane, P. De Truchis, B. Clair, M. Durigon, A. Sobel, and R. Gherardi. 1994. Zidovudine therapy and HIV encephalitis: a 10-year neuropathological survey. AIDS 8:489-493.
12. Gregersen, J. P., H. Wege, L. Preiss, and K. D. Jentsch. 1988. Detection of human immunodeficiency virus and other retroviruses in cell culture supernatants by a reverse transcriptase microassay. J. Virol. Methods 19:161-168.
13. Gu, Z., Q. Gao, X. Li, M. A. Parniak, and M. A. Wainberg. 1992. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross resistance to 2′-,3′-dideoxyinosine and 2′-,3′-dideoxycytidine. J. Virol. 66:7128-7135.
14. Gurusinghe, A. D., S. A. Land, C. Birch, C. McGavin, D. J. Hooker, G. Tachedjian, R. Doherty, and N. J. Deacon. 1995. Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS. J. Med. Virol. 46:238-243.
15. Harada, S., Y. Koyanagi, and N. Yamamoto. 1985. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 229:563-566.
16. Hultman, T., S. Stahl, E. Homes, and M. Uhlen. 1989. Direct solid-phase sequencing of genomic and plasmid DNA using magnetic heads as solid support. Nucleic Acids Res. 17:4937-4946.
17. Jacobo-Molina, A., J. Ding, R. G. Nanni, A. D. Clark, Jr., X. Lu, C. Tantillo, R. L. Williams, G. Kamer, A. L. Ferris, P. Clark, A. Hizi, S. H. Hughes, and E. Arnold. 1993. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Natl. Acad. Sci. USA 90:6320-6324.
18. Japour, A. J., S. Welles, R. T. D'Aquila, V. A. Johnson, D. D. Richman, R. W. Coombs, P. S. Reichelderfer, J. O. Kahn, C. S. Crumpacker, and D. R. Kuritzkes for the AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. 1995. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J. Infect. Dis. 171:1172-1179.
19. Jones, T. A., J. Y. Zou, S. W. Cowan, and M. Kjeldgaard. 1991. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. Sect. A 47:110-119.
20. Kaye, S., C. Loveday, and R. S. Tedder. 1992. A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type 1 infected patients treated with zidovudine. J. Med. Virol. 37:241-246.
21. Kellam, P., C. A. B. Boucher, and B. A. Larder. 1992. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 89:1934-1938.
22. Kellam, P., C. A. B. Boucher, J. M. G. H. Tijnagel, and B. A. Larder. 1994. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J. Gen. Virol. 75:341-351.
23. Kellam, P., and B. A. Larder. 1994. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 38:23-30.
24. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1992. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
25. Kozal, M. J., R. W. Shafer, M. A. Winters, D. A. Katzenstein, and T. C. Merigan. 1993. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J. Infect. Dis. 167:526-532.
26. Kraft, R., J. Tardiff, K. S. Krauter, and L. A. Leinwand. 1988. Using miniprep plasmid DNA for sequencing double-stranded templates with Sequenase. BioTechniques 6:544-547.
27. Land, S., C. McGavin, R. Lucas, and C. Birch. 1992. Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during and after therapy. J. Infect. Dis. 166:1139-1142.
28. Land, S., G. Treloar, D. McPhee, C. Birch, R. Doherty, D. Cooper, and I. Gust. 1990. Decreased in vitro susceptibility to zidovudine of HIV isolates ohtained from patients with AIDS. J. Infect. Dis. 161:326-329.
29. Larder, B. A. 1993. Inhibitors of HIV reverse transcriptase as antiviral agents and drug resistance, p. 205-222. In A. M. Skalka and S. P. Goff (ed.), Reverse transcriptase. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
30. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
31. Larder, B. A., P. Kellam, and S. D. Kemp. 1991. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 5:137-144.
32. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
33. Mayers, D. L., K. F. Wagner, R. C. Y, Chung, J. R. Lane, M. T. Vahey, F. A. White, N. M. Ruiz, C. B. Hicks, O. S. Weislow, L. I. Gardner, D. S. Burke, and the RV43 Study Group. 1993. Zidovudine (AZT) resistance is temporally associated with clinical failure in patients on AZT therapy, abstr. 3, session 8. In Program and abstracts of the First National Conference on Human Retroviruses and Related Infections. American Society for Microbiology. Washington, D.C.
34. Mellors, J. W., B. A. Larder, and R. F. Schinazi. 1994. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance, p. III-73-III-96. In G. Myers, B. Korber, S. Wain-Hobson, R. F. Smith, and G. N. Pavlakis (ed.), Human retroviruses and AIDS. Theoretical Biology and Biophysics Group T-10, Los Alamos National Laboratory, Los Alamos, N.Mex.
35. Merigan, T. C., G. Skowron, S. A. Bozzette, D. D. Richman, R. Uttamchandani, M. Fischl, R. Schooley, M. Hirsch, W. Soo, C. Pettinelli, H. Schaumberg, and the ddC Study Group of the AIDS Clinical Trials Group. 1989. Circulating p24 levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. Ann. Intern. Med. 110:189-194.
36. Mitsuya, H., and S. Broder. 1986. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′-. 3′-dideoxynucleosides. Proc. Natl. Acad. Sci. USA 83:1911-1915.
37. Mitsuya, H., K. J. Weinhold, P. A. Furman, M. H. St. Clair, S. N. Lehrman, R. C. Gallo, D. P. Bolognesi, D. W. Barry, and S. Broder. 1985. 3′-Azido-3′-deoxythymidine (BWA509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphocytotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA 82:7096-7100.
38. Muckenthaler, M., N. Gunkel, P. Levantis, K. Broadhurst, B. Goh, B. Colvin, G. Forster, G. G. Jackson, and J. S. Oxford. 1992. Sequence analysis of an HIV-1 isolate which displays unusually high-level AZT resistance in vitro. J. Med. Virol. 36:79-83.
39. Mulder, J. W., D. A. Cooper, L. Mathiesen, E. Sandström, N. Clumeck, J. M. Gatel, M. French, B. Donovan, F. Gray, J. M. Yeo, J. M. A. Lange, and The European-Australian Collaborative Group (Study 017). 1994. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomised, double-blind placebo-controlled study. AIDS 8:313-321.
40. Myers, G., B. Korber, S. Wain-Hobson, R. F. Smith, and G. N. Pavlakis (ed.). 1993. Human retroviruses and AIDS, p. I-A-84. Theoretical Biology and Biophysics Group T-10, Los Alamos National Laboratory, Los Alamos, N.Mex.
41. Nanni, R. G., J. Ding, A. Jacobo-Molina, S. H. Hughes, and E. Arnold. 1993. Review of HIV-1 reverse transcriptase three-dimensional structure: implications for drug design. Perspect. Drug Discov. Des. 1:129-150.
42. Neale, E. V., R. C. Pringle, J. B. M. Jowett, D. S. Healey, and I. D. Gust. 1987. Isolation of HIV from Australian patients with AIDS, AIDS-related conditions and healthy antibody positive individuals. Aust. N. Z. J. Med. 17:461-466.
43. Peden, K. W. C. 1992. Instability of HIV sequences in high copy number plasmids. J. Acquired Immune Defic. Syndr. 5:313-315.
44. Ratner, L., A. Fisher, L. L. Jagodzinski, H. Mitsuya, R.-S. Liou, R. C. Gallo, and F. Wong-Staal. 1987. Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res. Hum. Retroviruses 3:57-69.
45. Richman, D. D., J. M. Grimes, and S. W. Lagakos. 1990. Effect of stage of discase and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J. Acquired Immune Defic. Syndr. 3:743-746.
46. Rocancourt, D., C. Bonnerot, H. Jouin, M. Emerman, and J. F. Nicolas. 1990. Activation of a β-galactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-infected cells. J. Virol. 64:2660-2668.
47. Sayers, J. R., W. Schmidt, and F. Eckstein. 1988. 5′-3′ exonucleases in phosphorothioate-based oligonucleotide-directed mutagenesis. Nucleic Acids Res. 16:791-802.
48. Schinazi, R. F., R. M. Lloyd, Jr., M.-H. Nguyen, D. L, Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents. Chemother. 37:875-881.
49. Srinivasan, A., D. York, R. Jannoun-Nasr, S. Kalyanaraman, D. Swan, J. Benson, C. Bohan, P. A. Luciw, S. Schnoll, R. A. Robinson, S. M. Desai, and S. G. Devare. 1989. Generation of hybrid human immunodeficiency virus by homologous recombination. Proc. Natl. Acad. Sci. USA 86:6388-6392.
50. St. Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
51. Tachedjian, G., D. J. Hooker, A. D. Gurusinghe, H. Bazmi, N. J. Deacon, J. Mellors, C. Birch, and J. Mills. 1995. Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1. Virology 212:58-68.
52. Tachedjian, M., J. Krywult, R. J. Moore, and A. L. M. Hodgson. 1995. Caseous lymphadenitis vaccine development: site-specific inactivation of the Corynebacterium pseudotuberculosis phospholipase D gene. Vaccine 13:1785-1792.
53. Tantillo, C., J. Ding, A. Jacobo-Molina, R. G. Nanni, P. L. Boyer, S. H. Hughes, R. Pauwels, K. Andries, P. A. J. Janssen, and E. Arnold. 1994. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase: implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. 243:369-387.
54. Tisdale, M., S. D. Kemp, N. R. Ray, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
55. Valentine, F. T., M. Seidlin, H. Hochster, and M. Laverty. 1990. Phase I study of 2′-, 3′-dideoxyinosine: experience with 19 patients at New York University Medical Center. Rev. Infect. Dis. 12(Suppl. 5):S534-S539.
56. Van Leeuwen, R., J. M. A. Lange, E. K. Hussey, K. H. Donn, S. T. Hall, A. J. Harker, P. Jonker, and S. A. Danner. 1992. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS 6:1471-1475.
57. Whittington, R., and R. N. Brogden. 1992. Zalcitabine: a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS). Drugs 44:656-683.
58. Yarchoan, R., H. Mitsuya, R. V. Thomas, J. M. Pluda, N. R. Hartman, C-F. Perno, K. S. Marczyk, J.-P. Allain, D. G. Johns, and S. Broder. 1989. In vivo activity against HIV and favourable toxicity profile of 2′-,3′-dideoxyinosine. Science 245:412-415.
59. Yarchoan, R., C.-F. Perno, R. V. Thomas, R. W. Klecker, J.-P. Allain, R. J. Wills, N. McAtee, M. A. Fischl, R. Dubinsky, M. C. McNeely, H. Mitsuya, J. M. Pluda, T. J. Lawley, M. Leuther, B. Safai, J. M. Collins, C. E. Myers, and S. Broder. 1988. Phase I studies of 2′-.3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet i:76-81.
60. Yarchoan, R., K. J. Weinfold, H. K. Lyerly, E. Gelmann, R. M. Blum, G. M. Shearer, H. Mitsuya, J. M. Collins, C. E. Myers, R. W. Klecker, P. D. Markham, D. T. Durack, S. N. Lehrman, D. W. Barry, M. A. Fischl, R. C. Gallo, D. P. Bolognesi, and S. Broder. 1986. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet i:575-580.